Harnessing the Power of ROR1

VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.

About Us


ROR1 cell-surface protein is expressed on many hematologic and solid tumors. VelosBio’s proprietary ROR1-targeting technology allows the selective delivery of ROR1-directed therapies to tumors while sparing normal tissues.

Our Science
Homepage Bi Ab alt


Led by industry veterans with a track record of delivering new oncology drugs to patients, VelosBio Inc. is committed to improving patient outcomes by creating innovative targeted therapies for patients with hematologic and solid tumor malignancies.

Now Leaving The VelosBio Site.

Disclaimer Close Button SVG

Disclaimer: The information you have requested is not provided by VelosBio Inc. (“VelosBio”) but by a third party and should not be construed as representing the views of VelosBio. VelosBio does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom.

Continue Offsite